1. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry
- Author
-
Marianna Štefániková, Martina Doubková, Petra Ovesná, Martina Šterclová, Ladislav Lacina, Monika Žurková, Martina Plačková, Vladimír Bartoš, Ivana Janíčková, Radka Bittenglová, Jan Anton, Ľubica Sýkorová, Vladimíra Lošťáková, Pavlína Musilová, Hana Šuldová, Radka Mokošová, Jurij Didyk, Lenka Šišáková, Pavlína Lisá, Jaroslav Lněnička, Hana Dařičková, Daniel Doležel, Jana Pšikalová, Richard Tyl, Renata Králová, and Martina Koziar Vašáková
- Subjects
Pulmonary and Respiratory Medicine - Abstract
Introduction The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry. Patients/methods Data of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated. Results During 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p Conclusion Our real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.
- Published
- 2023
- Full Text
- View/download PDF